RS51530B - Novi 1,2,4-tiadiazolijum derivati kao modulatori melanokortinskog receptora - Google Patents

Novi 1,2,4-tiadiazolijum derivati kao modulatori melanokortinskog receptora

Info

Publication number
RS51530B
RS51530B YUP-397/04A YUP39704A RS51530B RS 51530 B RS51530 B RS 51530B YU P39704 A YUP39704 A YU P39704A RS 51530 B RS51530 B RS 51530B
Authority
RS
Serbia
Prior art keywords
alkyl
amino
alkoxy
aryl
heteroaryl
Prior art date
Application number
YUP-397/04A
Other languages
English (en)
Serbian (sr)
Inventor
Boyu Zhao
Magdalena Eisinger
Louis J. Fitzpatrick
Daniel H. Lee
Kevin Pan
Carlos Plata-Salaman
Allen B. Reitz
Virginia L. Smith-Swintosky
Original Assignee
Ortho-Mcneil Pharmaceutical Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho-Mcneil Pharmaceutical Inc. filed Critical Ortho-Mcneil Pharmaceutical Inc.
Publication of RS39704A publication Critical patent/RS39704A/sr
Publication of RS51530B publication Critical patent/RS51530B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/006—Antidandruff preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
YUP-397/04A 2001-11-08 2002-11-04 Novi 1,2,4-tiadiazolijum derivati kao modulatori melanokortinskog receptora RS51530B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33792701P 2001-11-08 2001-11-08
PCT/US2002/035340 WO2003040117A1 (en) 2001-11-08 2002-11-04 Novel 1,2,4-thiadiazole derivatives as melanocortin receptor modulators

Publications (2)

Publication Number Publication Date
RS39704A RS39704A (sr) 2006-10-27
RS51530B true RS51530B (sr) 2011-06-30

Family

ID=23322615

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-397/04A RS51530B (sr) 2001-11-08 2002-11-04 Novi 1,2,4-tiadiazolijum derivati kao modulatori melanokortinskog receptora

Country Status (26)

Country Link
US (2) US7049331B2 (https=)
EP (1) EP1446394B1 (https=)
JP (1) JP4436676B2 (https=)
CN (1) CN1312139C (https=)
AR (1) AR037331A1 (https=)
AT (1) ATE344254T1 (https=)
AU (1) AU2009201842B2 (https=)
BR (1) BR0214024A (https=)
CA (1) CA2466140C (https=)
CY (1) CY1105907T1 (https=)
DE (1) DE60215848T2 (https=)
DK (1) DK1446394T3 (https=)
ES (1) ES2275918T3 (https=)
IL (1) IL161829A (https=)
MX (1) MXPA04004458A (https=)
MY (1) MY134993A (https=)
NO (1) NO328195B1 (https=)
NZ (1) NZ532883A (https=)
PT (1) PT1446394E (https=)
RS (1) RS51530B (https=)
RU (1) RU2317292C2 (https=)
SG (1) SG176310A1 (https=)
SI (1) SI1446394T1 (https=)
TW (1) TWI328586B (https=)
WO (1) WO2003040117A1 (https=)
ZA (1) ZA200404484B (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732451B2 (en) 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US7456184B2 (en) 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7655658B2 (en) 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
CA2462200A1 (en) 2001-08-10 2003-02-20 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
NZ532883A (en) * 2001-11-08 2007-09-28 Ortho Mcneil Pharm Inc Novel 1,2,4-thiadiazole derivatives as melanocortin receptor modulators
US7319107B2 (en) * 2001-11-08 2008-01-15 Johnson & Johnson Consumer Companies, Inc. 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7968548B2 (en) * 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
WO2005054849A2 (en) * 2003-12-06 2005-06-16 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor mc5 (mc5r)
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
NZ550114A (en) 2004-04-20 2011-02-25 Transtech Pharma Inc Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators
EP2286840A3 (en) 2004-11-01 2013-09-04 Amylin Pharmaceuticals, LLC Treatment of obesity and related diseases
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
US20070021433A1 (en) 2005-06-03 2007-01-25 Jian-Qiang Fan Pharmacological chaperones for treating obesity
EP2330124B1 (en) 2005-08-11 2015-02-25 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
BRPI0614649A2 (pt) 2005-08-11 2011-04-12 Amylin Pharmaceuticals Inc polipeptìdeos hìbridos com propriedades selecionáveis
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
US7704533B2 (en) * 2006-12-13 2010-04-27 J&J Consumer Companies, Inc. Compositions and methods of inducing hair growth utilizing Continus coggygria
EP2101806B1 (en) * 2006-12-14 2013-05-01 NeuroNova AB Treatment of parkinson's disease or parkinsonian disorders using agents that decrease the activity of the melanocortin 4 receptor
RU2348623C1 (ru) * 2007-05-21 2009-03-10 Государственное образовательное учреждение высшего профессионального образования "Ивановский государственный химико-технологический университет" (ИГХТУ) Способ получения 3,5-диамино-1,2,4-тиадиазола
DK2278962T3 (en) 2008-02-21 2014-03-10 Janssen Pharmaceutica Nv Methods for the treatment of dermatological disorders
US8008291B2 (en) * 2008-02-29 2011-08-30 Mimetica Pty Ltd 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists
US8343958B2 (en) 2008-02-29 2013-01-01 Mimetica Pty Ltd 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5-receptor antagonists
US8377925B2 (en) * 2008-02-29 2013-02-19 Mimetica Pty Ltd Methods of modulating the activity of the MC5 receptor and treatment of conditions related to this receptor
US8563742B2 (en) 2008-08-29 2013-10-22 High Point Pharmaceuticals, Llc Substituted aminothiazole derivatives, pharmaceutical compositions, and methods of use
JP5514831B2 (ja) 2008-11-17 2014-06-04 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病の治療のための置換二環式アミン
SG10201401006QA (en) * 2009-04-24 2014-10-30 Janssen Pharmaceuticals Inc Stable topical compositions for 1,2,4-thiadiazole derivatives
WO2011011506A1 (en) 2009-07-23 2011-01-27 Schering Corporation Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
CA2768577A1 (en) 2009-07-23 2011-01-27 Schering Corporation Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors
ES2360783B1 (es) * 2009-10-02 2012-07-04 Consejo Superior De Investigaciones Científicas (Csic) 1,2,4-tiadiazoles-5-imino sustituidos utiles en el tratamiento de enfermedades neurodegenerativas
US8470880B2 (en) 2009-12-15 2013-06-25 Mcneil-Ppc, Inc. Methods of reducing hair loss and/or facilitating hair growth and/or regrowth
US8470833B2 (en) 2009-12-15 2013-06-25 Mcneil-Ppc, Inc. Hair growth and/or regrowth compositions
EP2563764B1 (en) 2010-04-26 2015-02-25 Merck Sharp & Dohme Corp. Novel spiropiperidine prolylcarboxypeptidase inhibitors
US9365539B2 (en) 2010-05-11 2016-06-14 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
US9006268B2 (en) 2010-06-11 2015-04-14 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
WO2012100342A1 (en) 2011-01-27 2012-08-02 Université de Montréal Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
CA3139033A1 (en) 2012-08-22 2014-02-27 Cornell University Methods for inhibiting fascin
US8962041B2 (en) 2013-02-12 2015-02-24 Johnson & Johnson Consumer Companies, Inc. Methods and compositions for enhancing hair quality using blackberry extract
CN111349087B (zh) 2014-02-20 2023-07-14 康奈尔大学 用于抑制肌成束蛋白的化合物和方法
WO2019241755A2 (en) * 2018-06-15 2019-12-19 Jay Dela Cruz Treatment of synucleinopathy and animal models of synucleinopathy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE131373C (https=)
JPS6011481A (ja) 1983-06-30 1985-01-21 Nippon Soda Co Ltd １，２，４−チアジアゾ−ル系誘導体及び農園芸用殺菌剤
JPH02173165A (ja) 1988-12-27 1990-07-04 Nippon Soda Co Ltd 防汚剤
HU224812B1 (en) * 1997-06-24 2006-02-28 Janssen Pharmaceutica Nv Angiogenesis inhibiting 5-substituted-1,2,4-thiadiazolyl derivatives, process for producing them and pharmaceutical compositions containing the same
AU3768799A (en) 1998-04-28 1999-11-16 Trega Biosciences, Inc. Isoquinoline compound melanocortin receptor ligands and methods of using same
JP2002513003A (ja) 1998-04-29 2002-05-08 セラニーズ・ヴェンチャーズ・ゲーエムベーハー 置換ビピリジル誘導体の触媒的製造法
AU742425B2 (en) 1998-06-11 2002-01-03 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
US6294534B1 (en) 1998-06-11 2001-09-25 Merck & Co., Inc. Spiropiperidine derivatives as melanocortin receptor agonists
AU1324300A (en) 1998-10-26 2000-05-15 Vertex Pharmaceuticals Incorporated Pentacyclic compounds useful as inhibitors of hepatitis c virus ns3 helicase
WO2001055107A2 (en) 2000-01-28 2001-08-02 Melacure Therapeutics Ab Aromatic amines and amides acting on the melanocortin receptors
NZ532883A (en) * 2001-11-08 2007-09-28 Ortho Mcneil Pharm Inc Novel 1,2,4-thiadiazole derivatives as melanocortin receptor modulators
US7319107B2 (en) * 2001-11-08 2008-01-15 Johnson & Johnson Consumer Companies, Inc. 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators

Also Published As

Publication number Publication date
US7375123B2 (en) 2008-05-20
JP4436676B2 (ja) 2010-03-24
ES2275918T3 (es) 2007-06-16
NO328195B1 (no) 2010-01-04
RS39704A (sr) 2006-10-27
RU2317292C2 (ru) 2008-02-20
IL161829A0 (en) 2005-11-20
TW200303311A (en) 2003-09-01
WO2003040117A1 (en) 2003-05-15
ZA200404484B (en) 2005-12-28
TWI328586B (en) 2010-08-11
EP1446394A1 (en) 2004-08-18
CA2466140A1 (en) 2003-05-15
BR0214024A (pt) 2004-12-07
RU2004114214A (ru) 2005-10-27
US20060128772A1 (en) 2006-06-15
DK1446394T3 (da) 2007-03-12
AU2009201842B2 (en) 2011-06-16
MY134993A (en) 2008-01-31
NO20042372L (no) 2004-06-07
PT1446394E (pt) 2007-01-31
ATE344254T1 (de) 2006-11-15
NZ532883A (en) 2007-09-28
SI1446394T1 (sl) 2007-04-30
AR037331A1 (es) 2004-11-03
CY1105907T1 (el) 2011-02-02
JP2005511605A (ja) 2005-04-28
IL161829A (en) 2010-11-30
DE60215848D1 (de) 2006-12-14
SG176310A1 (en) 2011-12-29
MXPA04004458A (es) 2005-06-08
CN1617862A (zh) 2005-05-18
US20030176425A1 (en) 2003-09-18
CA2466140C (en) 2011-02-01
DE60215848T2 (de) 2007-04-19
US7049331B2 (en) 2006-05-23
EP1446394B1 (en) 2006-11-02
AU2009201842A1 (en) 2009-06-04
CN1312139C (zh) 2007-04-25

Similar Documents

Publication Publication Date Title
RS51530B (sr) Novi 1,2,4-tiadiazolijum derivati kao modulatori melanokortinskog receptora
AU2002340372B2 (en) Novel 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators
AU2002340372A1 (en) Novel 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators
AU2002342318A1 (en) Novel 1,2,4-thiadiazole derivatives as melanocortin receptor modulators